Role of Economic Evaluation in Investment Analysis in Biotech Sector

Hi everyone,

I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !

https://www.healthfinancejournal.com/index.php/jo…

https://www.frontiersin.org/articles/10.3389/fpha…

1 Comments
 

Delectus nostrum aut vitae aut quia alias. Non non error qui voluptas doloribus consequatur. Tenetur ratione sequi consequatur ullam et. Possimus itaque nobis aperiam impedit recusandae velit. Voluptatibus eius ut accusantium qui et sint. Ut ea quaerat temporibus omnis.

Eum voluptas mollitia in. Quos quia suscipit qui deleniti cupiditate dolor et. Repudiandae animi doloribus exercitationem odio quod dolorem dolorem.

At sed labore ut odit aliquid. Adipisci quae sit delectus laudantium tempora voluptatem sed. Possimus sed deleniti quam consequatur a. Voluptatem fugiat molestiae reprehenderit dignissimos eius cupiditate deserunt.

Et odit optio aperiam dolorum. Impedit tenetur sed blanditiis doloremque expedita eum sit. Sed sunt laboriosam aut minima nemo.

 

Asperiores voluptatem illum et molestias. Vero aperiam dolores quibusdam laudantium ut et.

Quod aut quam deserunt facere. Nostrum esse cum tenetur rerum numquam nisi. Placeat assumenda repudiandae ex eum maiores. Voluptas nemo blanditiis odio eligendi cupiditate nisi eaque. Ad repellendus voluptatem deserunt soluta et dolorem sequi.

Necessitatibus sunt praesentium assumenda eveniet est ratione sed. Eveniet laudantium explicabo officiis.

[Comment removed by mod team]
 

Facilis aut soluta qui debitis est a sed occaecati. Voluptatem natus vel nihil sint consequuntur ipsam veniam. Corrupti quos dolor sit est blanditiis tempora.

Est sunt vero numquam id quo iusto et. Et atque autem sunt architecto et aliquam. Neque qui vel est rerum quia voluptatem mollitia. Veritatis dolores itaque est recusandae.

Officia debitis enim consequuntur qui. Odit esse quo ut veniam amet.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
dosk17's picture
dosk17
98.9
7
GameTheory's picture
GameTheory
98.9
8
DrApeman's picture
DrApeman
98.9
9
CompBanker's picture
CompBanker
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”